JP2019530724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530724A5 JP2019530724A5 JP2019520406A JP2019520406A JP2019530724A5 JP 2019530724 A5 JP2019530724 A5 JP 2019530724A5 JP 2019520406 A JP2019520406 A JP 2019520406A JP 2019520406 A JP2019520406 A JP 2019520406A JP 2019530724 A5 JP2019530724 A5 JP 2019530724A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- aryl
- heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims 64
- 229910052739 hydrogen Inorganic materials 0.000 claims 54
- 239000001257 hydrogen Substances 0.000 claims 50
- 125000000623 heterocyclic group Chemical group 0.000 claims 48
- 125000003118 aryl group Chemical group 0.000 claims 47
- 125000000547 substituted alkyl group Chemical group 0.000 claims 39
- 125000001072 heteroaryl group Chemical group 0.000 claims 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 34
- 125000002837 carbocyclic group Chemical group 0.000 claims 33
- 125000003710 aryl alkyl group Chemical group 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 150000002148 esters Chemical class 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 20
- 229940002612 prodrug Drugs 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 16
- -1 pyrrolidino, phenyl Chemical group 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000004429 atom Chemical group 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000010706 fatty liver disease Diseases 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 claims 5
- 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026589 Wolman disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002394 glycogenic effect Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical group CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409457P | 2016-10-18 | 2016-10-18 | |
| US62/409,457 | 2016-10-18 | ||
| PCT/US2017/057126 WO2018075608A1 (en) | 2016-10-18 | 2017-10-18 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530724A JP2019530724A (ja) | 2019-10-24 |
| JP2019530724A5 true JP2019530724A5 (enExample) | 2020-11-26 |
| JP7086948B2 JP7086948B2 (ja) | 2022-06-20 |
Family
ID=62018969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520406A Active JP7086948B2 (ja) | 2016-10-18 | 2017-10-18 | ピリミド－ジアゼピノンキナーゼ骨格化合物およびｄｃｌｋ１／２媒介性障害の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11028089B2 (enExample) |
| EP (1) | EP3528814B1 (enExample) |
| JP (1) | JP7086948B2 (enExample) |
| AU (1) | AU2017346845B2 (enExample) |
| CA (1) | CA3040173A1 (enExample) |
| WO (1) | WO2018075608A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11155556B2 (en) * | 2016-04-07 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders |
| AU2018392805A1 (en) | 2017-12-22 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | NEK inhibitors and methods of use |
| WO2020206608A1 (en) | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| WO2021024141A1 (en) * | 2019-08-08 | 2021-02-11 | Xiaoxiang Li | Prevention or treatment of diseases and disorders associated with tissue damage |
| CN115515588A (zh) | 2020-02-14 | 2022-12-23 | 萨克生物研究学院 | 大环ulk1/2抑制剂 |
| AU2021218739A1 (en) * | 2020-02-14 | 2022-09-22 | Salk Institute For Biological Studies | Inhibitors of ULK1/2 and methods of using same |
| US20240124460A1 (en) * | 2020-10-14 | 2024-04-18 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| EP4305040A1 (en) * | 2021-03-09 | 2024-01-17 | JANSSEN Pharmaceutica NV | Tricyclic pyridines as cyclin-dependent kinase 7 (cdk7) inhibitors |
| CN115707469B (zh) * | 2021-08-19 | 2024-07-02 | 首都医科大学附属北京朝阳医院 | Dclk1抑制剂和tki在制备肺腺癌药物中的应用 |
| CN114478539B (zh) * | 2022-02-09 | 2024-02-02 | 中国人民解放军海军军医大学 | 一种新型dclk1抑制剂及其制备方法和应用 |
| CN115969978A (zh) * | 2022-10-27 | 2023-04-18 | 首都医科大学附属北京朝阳医院 | Dclk1及il6/stat3通路抑制剂在治疗三阴性乳腺癌中的应用 |
| CN115814094B (zh) * | 2023-01-04 | 2024-04-02 | 暨南大学附属第一医院（广州华侨医院） | Dclk抑制剂在制备治疗脊髓损伤的药物中的应用 |
| CN116375713B (zh) * | 2023-03-07 | 2024-11-19 | 中国人民解放军海军军医大学 | 一种dclk1蛋白降解靶向嵌合体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2748181C (en) * | 2009-01-06 | 2019-07-16 | Nathanael S. Gray | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| US9453021B2 (en) | 2011-05-10 | 2016-09-27 | Kyowa Hakko Kirin Co., Ltd. | Pyrimidodiazepinone compound |
| WO2014160430A1 (en) * | 2013-03-13 | 2014-10-02 | Georgetown University | Small molecule lrrk2 and erk5 inhibitors |
| EP3670515B1 (en) | 2013-03-15 | 2024-03-06 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| WO2015117087A1 (en) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| JP2017504650A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| EP3177626A4 (en) * | 2014-08-08 | 2017-12-27 | Dana Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3424929A4 (en) | 2016-03-04 | 2019-08-07 | Anhui New Star Pharmaceutical Development Co., Ltd | PYRIMIDIN COMPOUNDS WITH SEVEN ELEMENTS, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION AND USES THEREOF |
-
2017
- 2017-10-18 US US16/343,102 patent/US11028089B2/en active Active
- 2017-10-18 WO PCT/US2017/057126 patent/WO2018075608A1/en not_active Ceased
- 2017-10-18 JP JP2019520406A patent/JP7086948B2/ja active Active
- 2017-10-18 CA CA3040173A patent/CA3040173A1/en active Pending
- 2017-10-18 AU AU2017346845A patent/AU2017346845B2/en active Active
- 2017-10-18 EP EP17862888.9A patent/EP3528814B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019094345A5 (enExample) | ||
| JP2020509022A5 (enExample) | ||
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2019529444A5 (enExample) | ||
| RU2019129727A (ru) | Применения пиримидопиримидинонов в качестве ингибиторов sik | |
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2019510787A5 (enExample) | ||
| JP2021535207A5 (enExample) | ||
| JP2016505586A5 (enExample) | ||
| JP2007508238A5 (enExample) | ||
| JP2019531346A5 (enExample) | ||
| JP2007515419A5 (enExample) | ||
| EP2123620A1 (en) | {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | |
| JP2023543254A5 (enExample) | ||
| AU2008216106C1 (en) | Cancer treatment method | |
| JP2005119987A (ja) | アシルスルホンアミド誘導体 | |
| JP2018507230A5 (enExample) | ||
| ES2911183T3 (es) | Compuesto para inhibir selectivamente quinasas y uso del mismo | |
| JP2023518775A5 (enExample) | ||
| RU2013107759A (ru) | Производные оксадиазола и пиридазина, их получение и применение в терапии | |
| JP2024502178A5 (enExample) | ||
| JP2021512075A (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| JP2020534266A5 (enExample) | ||
| MX2009002905A (es) | Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos. | |
| JP2023502745A5 (enExample) |